Citadel Advisors’s ProShares UltraShort NASDAQ Biotechnology BIS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-5,325
| Closed | -$187K | – | 14262 |
|
|
2024
Q1 | $187K | Buy |
5,325
+312
| +6% | +$11K | ﹤0.01% | 10423 |
|
|
2023
Q4 | $181K | Sell |
5,013
-6,169
| -55% | -$281K | ﹤0.01% | 10096 |
|
|
2023
Q3 | $501K | Buy |
11,182
+1,021
| +10% | +$43K | ﹤0.01% | 8070 |
|
|
2023
Q2 | $424K | Sell |
10,161
-1,130
| -10% | -$44.8K | ﹤0.01% | 8308 |
|
|
2023
Q1 | $458K | Buy |
+11,291
| New | +$449K | ﹤0.01% | 8497 |
|
|
2022
Q4 | – | Sell |
-12,903
| Closed | -$652K | – | 14876 |
|
|
2022
Q3 | $652K | Sell |
12,903
-4,583
| -26% | -$217K | ﹤0.01% | 7892 |
|
|
2022
Q2 | $943K | Buy |
17,486
+12,250
| +234% | +$685K | ﹤0.01% | 7152 |
|
|
2022
Q1 | $252K | Buy |
+5,236
| New | +$267K | ﹤0.01% | 10972 |
|
|
2021
Q2 | – | Sell |
-5,671
| Closed | -$256K | – | 13670 |
|
|
2021
Q1 | $256K | Buy |
+5,671
| New | +$238K | ﹤0.01% | 11184 |
|
|
2020
Q4 | – | Sell |
-4,104
| Closed | -$254K | – | 10909 |
|
|
2020
Q3 | $254K | Buy |
4,104
+61
| +2% | +$3.9K | ﹤0.01% | 8415 |
|
|
2020
Q2 | $259K | Sell |
4,043
-2,750
| -40% | -$214K | ﹤0.01% | 8147 |
|
|
2020
Q1 | $769K | Sell |
6,793
-3,794
| -36% | -$433K | ﹤0.01% | 5768 |
|
|
2019
Q4 | $1.14M | Buy |
10,587
+967
| +10% | +$124K | ﹤0.01% | 5364 |
|
|
2019
Q3 | $1.54M | Buy |
9,620
+3,700
| +63% | +$543K | ﹤0.01% | 4885 |
|
|
2019
Q2 | $807K | Sell |
5,920
-329
| -5% | -$48.1K | ﹤0.01% | 6047 |
|
|
2019
Q1 | $836K | Sell |
6,249
-514
| -8% | -$72.6K | ﹤0.01% | 5911 |
|
|
2018
Q4 | $1.24M | Buy |
6,763
+2,556
| +61% | +$412K | ﹤0.01% | 4968 |
|
|
2018
Q3 | $526K | Buy |
4,207
+1,075
| +34% | +$145K | ﹤0.01% | 6609 |
|
|
2018
Q2 | $488K | Buy |
3,132
+991
| +46% | +$165K | ﹤0.01% | 6416 |
|
|
2018
Q1 | $362K | Buy |
2,141
+513
| +32% | +$82.4K | ﹤0.01% | 6439 |
|
|
2017
Q4 | $287K | Buy |
1,628
+94
| +6% | +$16.7K | ﹤0.01% | 6532 |
|
|
2017
Q3 | $252K | Buy |
1,534
+477
| +45% | +$86K | ﹤0.01% | 6331 |
|
|
2017
Q2 | $205K | Sell |
1,057
-1,453
| -58% | -$317K | ﹤0.01% | 6532 |
|
|
2017
Q1 | $559K | Buy |
2,510
+1,677
| +201% | +$396K | ﹤0.01% | 4825 |
|
|
2016
Q4 | $233K | Buy |
+833
| New | +$228K | ﹤0.01% | 6070 |
|
|
2016
Q1 | – | Sell |
-10,069
| Closed | -$2.31M | – | 6796 |
|
|
2015
Q4 | $2.31M | Buy |
10,069
+241
| +2% | +$62K | ﹤0.01% | 2590 |
|
|
2015
Q3 | $3.03M | Buy |
9,828
+8,092
| +466% | +$1.91M | ﹤0.01% | 2452 |
|
|
2015
Q2 | $399K | Buy |
+1,736
| New | +$431K | ﹤0.01% | 5319 |
|
|
2015
Q1 | – | Sell |
-529
| Closed | -$195K | – | 8525 |
|
|
2014
Q4 | $195K | Buy |
+529
| New | +$220K | ﹤0.01% | 6003 |
|
Other funds holding BIS
TRCT
Citadel Advisors's BIS Position: Q2 2024 in Review
Citadel Advisors sold out of ProShares UltraShort NASDAQ Biotechnology (BIS) in Q2 2024, closing a stake of 5,325 shares — an estimated $187K sold.
Citadel Advisors first reported a position in BIS in Q4 2014 and held it in 29 quarters. The position peaked at $3.03M in Q3 2015. 6 funds tracked by Wall St. Rank hold BIS as of Q2 2024.
- Citadel Advisors reported no remaining ProShares UltraShort NASDAQ Biotechnology position as of Q2 2024 after selling out during the quarter.
- Citadel Advisors sold 5,325 ProShares UltraShort NASDAQ Biotechnology shares in Q2 2024, an estimated $187K.
- Citadel Advisors first reported a position in ProShares UltraShort NASDAQ Biotechnology in Q4 2014 and held it in 29 quarters.
- Citadel Advisors's ProShares UltraShort NASDAQ Biotechnology position peaked at $3.03M in Q3 2015.
- 6 funds tracked by Wall St. Rank held ProShares UltraShort NASDAQ Biotechnology as of Q2 2024.
Based on Citadel Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.